Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.42 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.42 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 17/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.37 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.37 |
| ▸ | CCNC | P24863 | 1/20 | 0.34 |
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15522951 | 0.83 | PARP1 (0.36) | PARP1PARP10PARP11 | |
| SCHEMBL7644556 | 0.77 | MEN1 (0.53) | MEN1TNNI3TNNT2TNNC1KMT2A | |
| SCHEMBL14096271 | 0.72 | MEN1 (0.42) | MEN1TNNI3TNNT2TNNC1KMT2A | |
| SCHEMBL1533025 | 0.72 | PARP10 (0.46) | PARP1PARP10PARP11 | |
| SCHEMBL6202369 | 0.72 | HTR2C (0.53) | HTR2CHTR2BPARP1PARP10PARP11 | |
| SCHEMBL15522811 | 0.71 | HTR2C (0.76) | HTR2AHTR2CHTR2B | |
| SCHEMBL7649483 | 0.70 | MEN1 (0.71) | MEN1TNNI3TNNT2TNNC1KMT2A | |
| SCHEMBL15578653 | 0.69 | MEN1 (0.41) | MEN1TNNI3TNNT2TNNC1KMT2A | |
| SCHEMBL22393385 | 0.67 | HTR2A (0.39) | MEN1TNNI3TNNT2TNNC1KMT2A | |
| SCHEMBL2060502 | 0.65 | PARP1 (0.51) | PARP1PARP10PARP11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200283439-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | AbbVie Deutschland GmbH & Co. KG (DE) | 2020-09-10 | — | — | US | claimed |
| US-20190071443-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-03-07 | — | — | US | claimed |
| US-20160016954-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-21 | — | — | US | claimed |
| US-20140080816-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-03-20 | — | — | US | claimed |
| US-20140080814-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-03-20 | — | — | US | claimed |
| US-20140080813-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | ABBVIE DEUTSCHLAND (DE) | 2014-03-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080813-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | HTR2C, HTR2A, HTR5A | MEN1 2568/4885TNNI3 1258/4885TNNT2 1195/4885 |
| US-20160016954-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | HTR2C, HTR2A, HTR5A | MEN1 2568/4885TNNI3 1258/4885TNNT2 1195/4885 |
| US-20140080816-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | HTR2C, HTR2A, HTR5A | MEN1 2568/4885TNNI3 1258/4885TNNT2 1195/4885 |
| US-20200283439-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | HTR2C, HTR2A, HTR5A | MEN1 2568/4885TNNI3 1258/4885TNNT2 1195/4885 |
| US-20140080814-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | HTR2C, HTR2A, HTR5A | MEN1 2568/4885TNNI3 1258/4885TNNT2 1195/4885 |
| US-20190071443-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | HTR2C, HTR2A, HTR5A | MEN1 2568/4885TNNI3 1258/4885TNNT2 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.